Oncotarget: Predictive biomarkers in Trop-2-expressing triple-negative breast cancer

(Impact Journals LLC) SG could provide better clinical benefit than irinotecan in patients with HRR-proficient tumors expressing high levels of Trop-2, as well as to patients with HRR-deficient tumors expressing low/moderate levels of Trop-2.